Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 99 articles:
HTML format
Text format



Single Articles


    March 2019
  1. GIANNINI R, Moretti S, Ugolini C, Macerola E, et al
    Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like.
    J Clin Endocrinol Metab. 2019 Mar 18. pii: 5381919. doi: 10.1210/jc.2018-01167.
    PubMed     Text format     Abstract available


    February 2019
  2. LI J, An C, Zheng H, Lei T, et al
    Leukocyte telomere length and risk of papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2019 Feb 28. pii: 5365821. doi: 10.1210/jc.2018-02471.
    PubMed     Text format     Abstract available


    August 2018
  3. PARK SY, Cho YY, Kim HI, Choe JH, et al
    Clinical validation of the prognostic stage groups of the eighth edition TNM staging for medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Aug 17. pii: 5075160. doi: 10.1210/jc.2018-01386.
    PubMed     Text format     Abstract available


    July 2018
  4. KLUBO-GWIEZDZINSKA J, Wartofsky L
    Commentary on: "Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules".
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055545. doi: 10.1210/jc.2018-01081.
    PubMed     Text format    


  5. TURNBULL C, Loveday C, Izatt L, Ellard S, et al
    Response to Letter to the Editor regarding : "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer" from Andreas Machens and Henning Dralle.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055548. doi: 10.1210/jc.2018-01094.
    PubMed     Text format    


  6. PANDYA A, Caoili EM, Jawad-Makki F, Wasnik AP, et al
    Limitations of the 2015 ATA Guidelines for Prediction of Thyroid Cancer: A Review of 1,947 Consecutive Aspirations.
    J Clin Endocrinol Metab. 2018 Jul 3. pii: 5047770. doi: 10.1210/jc.2018-00792.
    PubMed     Text format     Abstract available


  7. CHERELLA CE, Feldman HA, Hollowell M, Richman DM, et al
    Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047287. doi: 10.1210/jc.2018-00895.
    PubMed     Text format     Abstract available


    June 2018
  8. MACHENS A, Dralle H
    Letter to the Editor: "p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer".
    J Clin Endocrinol Metab. 2018 Jun 26. pii: 5043208. doi: 10.1210/jc.2018-00906.
    PubMed     Text format    



  9. CORRIGENDUM FOR "DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma".
    J Clin Endocrinol Metab. 2018 Jun 4. pii: 5032648. doi: 10.1210/jc.2018-01190.
    PubMed     Text format    


  10. SADOWSKI SM, Pusztaszeri M, Brulhart-Meynet MC, Petrenko V, et al
    Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2018;103:2189-2198.
    PubMed     Text format     Abstract available


    May 2018
  11. PARK J, Blackburn BE, Ganz PA, Rowe K, et al
    Risk Factors for Cardiovascular Disease among Thyroid Cancer Survivors: Findings from the Utah Cancer Survivors Study.
    J Clin Endocrinol Metab. 2018 May 29. pii: 5005948. doi: 10.1210/jc.2017-02629.
    PubMed     Text format     Abstract available


  12. MACFARLAND SP, Bauer AJ, Adzick NS, Surrey LF, et al
    Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 May 18. pii: 4998998. doi: 10.1210/jc.2018-00026.
    PubMed     Text format     Abstract available


  13. BANERJEE M, Reyes-Gastelum D, Haymart MR
    Treatment-free Survival in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2018 May 16. pii: 4996515. doi: 10.1210/jc.2018-00511.
    PubMed     Text format     Abstract available


  14. NICOLSON NG, Murtha TD, Dong W, Paulsson JO, et al
    Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology.
    J Clin Endocrinol Metab. 2018 May 2. pii: 4990776. doi: 10.1210/jc.2018-00277.
    PubMed     Text format     Abstract available


  15. LIVHITS M
    Response to Letter to the Editor: "Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015".
    J Clin Endocrinol Metab. 2018;103:2073.
    PubMed     Text format    


  16. YLLI D, Burman KD, Van Nostrand D, Wartofsky L, et al
    Eliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road?
    J Clin Endocrinol Metab. 2018;103:1813-1817.
    PubMed     Text format     Abstract available


    April 2018
  17. TRAN B DR., Roshan D Mr., Abraham E Dr., Wang L Dr., et al
    An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970148. doi: 10.1210/jc.2017-02551.
    PubMed     Text format     Abstract available


  18. MAINO F, Forleo R, Martinelli M, Fralassi N, et al
    Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970151. doi: 10.1210/jc.2018-00274.
    PubMed     Text format     Abstract available


  19. JABER T, Hyde SM, Cote GJ, Grubbs EG, et al
    A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    J Clin Endocrinol Metab. 2018;103:1269-1272.
    PubMed     Text format     Abstract available


    March 2018
  20. KITAHARA CM, Farkas DKR, Jorgensen JOL, Cronin-Fenton D, et al
    Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951500. doi: 10.1210/jc.2017-02599.
    PubMed     Text format     Abstract available


  21. LIVHITS MJ, Kuo EJ, Leung AM, Rao J, et al
    Gene Expression Classifier versus Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 23. pii: 4951503. doi: 10.1210/jc.2017-02754.
    PubMed     Text format     Abstract available


  22. WU D, Guan H
    Letter to the Editor: "Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015".
    J Clin Endocrinol Metab. 2018 Mar 13. pii: 4931670. doi: 10.1210/jc.2018-00333.
    PubMed     Text format    


  23. GANNON AW, Langer JE, Bellah R, Ratcliffe S, et al
    Diagnostic Accuracy of Ultrasound with Color Flow Doppler in Children with Thyroid Nodules.
    J Clin Endocrinol Metab. 2018 Mar 12. pii: 4931064. doi: 10.1210/jc.2017-02464.
    PubMed     Text format     Abstract available


    February 2018
  24. WASSERMAN JD, Sabbaghian N, Fahiminiya S, Chami R, et al
    DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Feb 21. pii: 4893697. doi: 10.1210/jc.2017-02698.
    PubMed     Text format     Abstract available


  25. SAMUELS SL, Surrey LF, Hawkes CP, Amberge M, et al
    Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort.
    J Clin Endocrinol Metab. 2018 Feb 8. pii: 4844750. doi: 10.1210/jc.2017-02454.
    PubMed     Text format     Abstract available


  26. PERSICHETTI A, Di Stasio E, Guglielmi R, Bizzarri G, et al
    Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems. A Prospective Study.
    J Clin Endocrinol Metab. 2018 Feb 1. pii: 4834029. doi: 10.1210/jc.2017-01708.
    PubMed     Text format     Abstract available


    January 2018
  27. GIORDANO TJ, Haugen B, Sherman SI, Shah MH, et al
    Pioglitazone Therapy of PAX8-PPARgamma Fusion Protein Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Jan 24. pii: 4822913. doi: 10.1210/jc.2017-02533.
    PubMed     Text format     Abstract available


  28. TARABICHI M, Antoniou A, Le Pennec S, Gacquer D, et al
    Distinctive desmoplastic 3D morphology associated with BRAFV600E in papillary thyroid cancers.
    J Clin Endocrinol Metab. 2018 Jan 12. pii: 4801233. doi: 10.1210/jc.2017-02279.
    PubMed     Text format     Abstract available


  29. RAUE F, Dralle H, Machens A, Bruckner T, et al
    Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium.
    J Clin Endocrinol Metab. 2018;103:235-243.
    PubMed     Text format     Abstract available


    December 2017
  30. PRATHEESHKUMAR P, Siraj AK, Divya SP, Parvathareddy SK, et al
    Downregulation of SKP2 in papillary thyroid cancer acts synergistically with TRAIL on inducing apoptosis via ROS.
    J Clin Endocrinol Metab. 2017 Dec 28. pii: 4780811. doi: 10.1210/jc.2017-02178.
    PubMed     Text format     Abstract available


  31. PARK KW, Wu JX, Du L, Leung AM, et al
    Decreasing use of radioactive iodine for low risk thyroid cancer in California, 1999-2015.
    J Clin Endocrinol Metab. 2017 Dec 15. pii: 4743227. doi: 10.1210/jc.2017-02269.
    PubMed     Text format     Abstract available


  32. SHIMURA H, Sobue T, Takahashi H, Yasumura S, et al
    Findings of thyroid ultrasound examination within three years after the Fukushima Nuclear Power Plant accident: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2017 Dec 14. pii: 4630428. doi: 10.1210/jc.2017-01603.
    PubMed     Text format     Abstract available


  33. RITTER A, Bachar G, Hirsch D, Benbassat C, et al
    Natural History of Contralateral Nodules after Lobectomy in Patients with Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017 Dec 12. pii: 4731740. doi: 10.1210/jc.2017-01616.
    PubMed     Text format     Abstract available


  34. SHAH S, Boucai L
    Effect of Age on Response to Therapy and Mortality in Patients with Thyroid Cancer at High-Risk of Recurrence.
    J Clin Endocrinol Metab. 2017 Dec 6. pii: 4693942. doi: 10.1210/jc.2017-02255.
    PubMed     Text format     Abstract available


  35. VAN DER TUIN K, Tops CMJ, Adank MA, Cobben JM, et al
    CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2017;102:4534-4540.
    PubMed     Text format     Abstract available


  36. KIM HI, Jang HW, Ahn HS, Ahn S, et al
    High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance.
    J Clin Endocrinol Metab. 2017 Dec 1. pii: 4677373. doi: 10.1210/jc.2017-01775.
    PubMed     Text format     Abstract available


    November 2017
  37. WATANABE N, Narimatsu H, Noh JY, Iwaku K, et al
    Long-term outcomes of 107 cases of primary thyroid MALT lymphoma at a single medical institution in Japan.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01478.
    PubMed     Text format     Abstract available


  38. KLEIN HESSELINK EN, Zafon C, Villalmanzo N, Iglesias C, et al
    Increased global DNA hypomethylation in distant metastatic and dedifferentiated thyroid cancer.
    J Clin Endocrinol Metab. 2017 Nov 20. doi: 10.1210/jc.2017-01613.
    PubMed     Text format     Abstract available


  39. HE H, Li W, Liyanarachchi S, Wang Y, et al
    The role of NRG1 in the predisposition to papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01798.
    PubMed     Text format     Abstract available


  40. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Text format     Abstract available


  41. HIRSCH D, Gorshtein A, Robenshtok E, Masri-Iraqi H, et al
    Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer with Loforegional Persistent Disease.
    J Clin Endocrinol Metab. 2017 Nov 3. doi: 10.1210/jc.2017-01790.
    PubMed     Text format     Abstract available


  42. CASEY RT, Warren AY, Martin JE, Challis BG, et al
    Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
    J Clin Endocrinol Metab. 2017;102:4013-4022.
    PubMed     Text format     Abstract available


    October 2017

  43. CORRIGENDUM FOR Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017 Oct 24. doi: 10.1210/jc.2017-02312.
    PubMed     Text format    


  44. ANGELL TE, Vyas C, Medici M, Wang Z, et al
    Differential Growth Rates of Benign versus Malignant Thyroid Nodules.
    J Clin Endocrinol Metab. 2017 Oct 12. doi: 10.1210/jc.2017-01832.
    PubMed     Text format     Abstract available


  45. PRASONGSOOK N, Kumar A, Chintakuntlawar AV, Foote RL, et al
    Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Oct 5. doi: 10.1210/jc.2017-01180.
    PubMed     Text format     Abstract available


    September 2017
  46. VOSS RK, Grubbs EG
    Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3559.
    PubMed     Text format    


  47. CASTINETTI F, Whollk N
    Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3557-3558.
    PubMed     Text format    


  48. COTE GJ, Evers C, Hu MI, Grubbs EG, et al
    Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017;102:3591-3599.
    PubMed     Text format     Abstract available


  49. VIOLA D, Giani C, Mazzeo S, Ugolini C, et al
    KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
    J Clin Endocrinol Metab. 2017;102:3091-3096.
    PubMed     Text format     Abstract available


    August 2017
  50. DOS REIS MB, Barros-Filho MC, Marchi FA, Beltrami CM, et al
    Prognostic classifier based on genome-wide DNA methylation profiling in well-differentiated thyroid tumors.
    J Clin Endocrinol Metab. 2017 Aug 16. doi: 10.1210/jc.2017-00881.
    PubMed     Text format     Abstract available


    July 2017
  51. FRENCH JD, Haugen BR
    Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies?
    J Clin Endocrinol Metab. 2017;102:2131-2132.
    PubMed     Text format    


    June 2017
  52. SZCZEPANEK-PARULSKA E, Zybek-Kocik A, Wartofsky L, Ruchala M, et al
    Thyroid hemiagenesis: incidence, clinical significance and genetic background.
    J Clin Endocrinol Metab. 2017 Jun 28. doi: 10.1210/jc.2017-00784.
    PubMed     Text format     Abstract available


  53. ROSSFELD KK, Justiniano SE, Ding H, Gong L, et al
    Biological evaluation of a novel fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model.
    J Clin Endocrinol Metab. 2017 Jun 7. doi: 10.1210/jc.2017-00573.
    PubMed     Text format     Abstract available


  54. WANG F, Yu X, Shen X, Zhu G, et al
    The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Jun 5. doi: 10.1210/jc.2017-00277.
    PubMed     Text format     Abstract available


  55. MATHIESEN JS, Habra MA, Bassett JHD, Choudhury SM, et al
    Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
    J Clin Endocrinol Metab. 2017;102:2069-2074.
    PubMed     Text format     Abstract available


  56. MOMESSO DP, Tuttle RM
    Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2115-2116.
    PubMed     Text format    


  57. GIOVANELLA L, Cosma C, Plebani M
    Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    J Clin Endocrinol Metab. 2017;102:2113-2114.
    PubMed     Text format    


    May 2017
  58. LEE JJ, Wang TY, Liu CL, Chien MN, et al
    Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 May 26. doi: 10.1210/jc.2017-00346.
    PubMed     Text format     Abstract available


  59. VOSS RK, Feng L, Lee JE, Perrier ND, et al
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness
    J Clin Endocrinol Metab. 2017 May 9. doi: 10.1210/jc.2017-00317.
    PubMed     Text format     Abstract available


  60. IMAIZUMI M, Ohishi W, Nakashima E, Sera N, et al
    Thyroid dysfunction and autoimmune thyroid diseases among atomic-bomb survivors exposed in childhood.
    J Clin Endocrinol Metab. 2017 May 1. doi: 10.1210/jc.2017-00102.
    PubMed     Text format     Abstract available


  61. ELISEI R, Binchi F, Matrone A
    Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1785-1786.
    PubMed     Text format    


  62. GIOVANELLA L, Ceriani L, Trimboli P
    Letter to the Editor: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    J Clin Endocrinol Metab. 2017;102:1783-1784.
    PubMed     Text format    


    April 2017
  63. PAPALEONTIOU M, Hughes DT, Guo C, Banerjee M, et al
    Population-Based Assessment of Complications following Surgery for Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 28. doi: 10.1210/jc.2017-00255.
    PubMed     Text format     Abstract available


  64. WASSNER AJ, Della Vecchia M, Jarolim P, Feldman HA, et al
    Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 10. doi: 10.1210/jc.2017-00286.
    PubMed     Text format     Abstract available


    March 2017
  65. CAHOON EK, Nadirov EA, Polanskaya ON, Yauseyenka VV, et al
    Risk of thyroid nodules in residents of Belarus exposed to Chernobyl fallout as children and adolescents.
    J Clin Endocrinol Metab. 2017 Mar 22. doi: 10.1210/jc.2016-3842.
    PubMed     Text format     Abstract available


  66. LUBIN JH, Adams MJ, Shore R, Holmberg E, et al
    Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts.
    J Clin Endocrinol Metab. 2017 Mar 8. doi: 10.1210/jc.2016-3529.
    PubMed     Text format     Abstract available


  67. MELO M, Gaspar da Rocha A, Batista R, Vinagre J, et al
    TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2785.
    PubMed     Text format     Abstract available


  68. KWON H, Oh HS, Kim M, Park S, et al
    Active Surveillance for Patients with Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea.
    J Clin Endocrinol Metab. 2017 Mar 3. doi: 10.1210/jc.2016-4026.
    PubMed     Text format     Abstract available


    February 2017
  69. KIM TH, Ki CS, Kim HS, Kim K, et al
    Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations.
    J Clin Endocrinol Metab. 2017 Feb 28. doi: 10.1210/jc.2016-3434.
    PubMed     Text format     Abstract available


  70. KHAN NE, Bauer AJ, Schultz KA, Doros L, et al
    Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.
    J Clin Endocrinol Metab. 2017 Feb 2. doi: 10.1210/jc.2016-2954.
    PubMed     Text format     Abstract available


    January 2017
  71. CHOKSI P, Papaleontiou M, Guo C, Worden F, et al
    Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.
    J Clin Endocrinol Metab. 2017 Jan 25. doi: 10.1210/jc.2016-3906.
    PubMed     Text format     Abstract available


  72. PARK S, Jeon MJ, Song E, Oh HS, et al
    Clinical Features of Early and Late Postoperative Hypothyroidism after Lobectomy.
    J Clin Endocrinol Metab. 2017 Jan 11. doi: 10.1210/jc.2016-3597.
    PubMed     Text format     Abstract available


    December 2016
  73. BAGHERI-YARMAND R, Williams MD, Grubbs EG, Gagel RF, et al
    ATF4 Targets RET for Degradation and is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Dec 9:jc20162878.
    PubMed     Text format     Abstract available


  74. MATRONE A, Gambale C, Piaggi P, Viola D, et al
    Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation.
    J Clin Endocrinol Metab. 2016 Dec 8:jc20162860.
    PubMed     Text format     Abstract available


    November 2016
  75. SCHNEIDER TC, de Wit D, Links TP, van Erp NP, et al
    Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
    J Clin Endocrinol Metab. 2016 Nov 21:jc20162525.
    PubMed     Text format     Abstract available


  76. EHLERS M, Kuebart A, Hautzel H, Enczmann J, et al
    Epitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 18:jc20162469.
    PubMed     Text format     Abstract available


  77. MAROTTA V, Sciammarella C, Capasso M, Testori A, et al
    Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 16:jc20162555.
    PubMed     Text format     Abstract available


  78. SUNG TY, Jeon MJ, Lee YH, Lee YM, et al
    Initial and Dynamic Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Nov 3:jc20162666.
    PubMed     Text format     Abstract available


    October 2016
  79. WANG W, Kang H, Zhao Y, Min I, et al
    Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.
    J Clin Endocrinol Metab. 2016 Oct 18:jc20161999.
    PubMed     Text format     Abstract available


  80. ZHANG Y, Sui F, Ma J, Ren X, et al
    Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20161677.
    PubMed     Text format     Abstract available


  81. HWANGBO Y, Kim JM, Park YJ, Lee EK, et al
    Long-term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162287.
    PubMed     Text format     Abstract available


    September 2016
  82. KIM SW, Song SH, Lee HS, Noh WJ, et al
    Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging.
    J Clin Endocrinol Metab. 2016 Sep 20:jc20162558.
    PubMed     Text format     Abstract available


  83. UCHINO S, Ishikawa H, Miyauchi A, Hirokawa M, et al
    Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis.
    J Clin Endocrinol Metab. 2016 Sep 13:jc20162043.
    PubMed     Text format     Abstract available


    August 2016
  84. YU XU J, Handy B, Michaelis CL, Waguespack SG, et al
    Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 30:jc20162567.
    PubMed     Text format     Abstract available


  85. ROBINSON B, Schlumberger M, Wirth LJ, Dutcus CE, et al
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 22:jc20153989.
    PubMed     Text format     Abstract available


  86. HOLLINGSWORTH B, Senter L, Zhang X, Brock GN, et al
    Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2016 Aug 17:jc20161605.
    PubMed     Text format     Abstract available


  87. PALERMO A, Mangiameli G, Tabacco G, Longo F, et al
    PTH(1-34) for the primary prevention of post-thyroidectomy hypocalcemia: the THYPOS trial.
    J Clin Endocrinol Metab. 2016 Aug 15:jc20162530.
    PubMed     Text format     Abstract available


  88. LY S, Frates MC, Benson CB, Peters HE, et al
    Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center.
    J Clin Endocrinol Metab. 2016 Aug 8:jc20161779.
    PubMed     Text format     Abstract available


  89. LABOURIER E
    Letter to the Editor: The Value of Molecular Testing for Effective Management of Patients With Indeterminate Thyroid Nodules.
    J Clin Endocrinol Metab. 2016;101:L76-7.
    PubMed     Text format    


    July 2016
  90. LIYANARACHCHI S, Li W, Yan P, Bundschuh R, et al
    Genome-wide expression screening discloses long noncoding RNAs involved in thyroid carcinogenesis.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20161991.
    PubMed     Text format     Abstract available


  91. LUO J, Hendryx M, Manson JE, Liang X, et al
    Hysterectomy, oophorectomy and risk of thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20162011.
    PubMed     Text format     Abstract available


    May 2016
  92. LAMARTINA L, Grani G, Biffoni M, Giacomelli L, et al
    Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 May 17:jc20161440.
    PubMed     Text format     Abstract available


    April 2016
  93. LAMARTINA L, Ippolito S, Danis M, Bidault F, et al
    Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer.
    J Clin Endocrinol Metab. 2016 Apr 15:jc20154391.
    PubMed     Text format     Abstract available


  94. BASTMAN JJ, Serracino HS, Zhu Y, Koenig MR, et al
    Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Apr 5:jc20154227.
    PubMed     Text format     Abstract available


    March 2016
  95. MOMESSO DP, Vaisman F, Yang SP, Bulzico DA, et al
    DYNAMIC RISK STRATIFICATION IN DIFFERENTIATED THYROID CANCER PATIENTS TREATED WITHOUT RADIOACTIVE IODINE.
    J Clin Endocrinol Metab. 2016 Mar 29:jc20154290.
    PubMed     Text format     Abstract available


  96. BURCH HB, Burman KD, Cooper DS, Hennessey JV, et al
    A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.
    J Clin Endocrinol Metab. 2016 Mar 25:jc20161155.
    PubMed     Text format     Abstract available


  97. LAZAR L, Lebenthal Y, Segal K, Steinmetz A, et al
    Pediatric thyroid cancer: postoperative classifications and response-to-initial-therapy as prognostic factors.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20153960.
    PubMed     Text format     Abstract available


    February 2016
  98. AHN D, Ho Sohn J, Han Jeon J
    Hypothyroidism following hemithyroidectomy: incidence, risk factors, and clinical characteristics.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153997.
    PubMed     Text format     Abstract available


  99. BIKAS A, Schneider M, Desale S, Atkins F, et al
    Effects of Dosimetrically-Guided I-131 Therapy on Hematopoiesis in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153544.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: